Latest Scientific Articles Across Therapeutic Areas

A talk by Dr. Reyna Daya on the relationship between diabetes and aging, highlighting the treatment goals and pharmacological therapy for the elderly patient.

A talk by Dr. Hoosen Randeree on what a Diabetologist needs to know on diabetes and chronic kidney disease.

What for you are the key findings of the Toujeo® pooled analysis?

What would you say is the value of the findings in the Toujeo^® pooled analysis and the DELIVER-G study when you consider the management of your patients with type 2 diabetes who are inadequately controlled on GLP-1 receptor agonist?

In what way does the evidence for Toujeo^® help you to address the considerations for patients who are inadequately controlled on a GLP-1 receptor agonist?

Perspectives on basal insulin use post-GLP-1 RA, EASD, Dr Alice Cheng

A video about the challenges that Type 1 Diabetes patients face when exercising.

Skeletal involvement remains one of the most challenging aspects of Gaucher disease to manage, often responding more slowly to treatment than haematological or visceral disease. This expert interview explores a treat-to-target approach to optimising enzyme replacement therapy dosing specifically for bone-related outcomes. The discussion covers how skeletal response is assessed and when dose optimisation may be considered. Content is intended for specialists managing the long-term skeletal complications of Gaucher disease.